Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • Meet the Team
  • Services
    • Biobank Core Services
    • Bioinformatics and Statistics Core
    • Functional Genomics (Zebrafish) Core
    • Gene Transfer Vector
      • Rates
      • Order Information
      • Contact Us
    • Genetic Diagnostic Testing Service
      • Pricing
    • Genomics Core Services
      • Additional Genomics Services
      • Sanger Sequencing
      • Array Analysis
      • Next-Generation Sequencing (NGS)
  • Labs
    • Biobank Core
    • Bujakowska Lab
      • Lab Members
      • Publications
    • Comander Lab
      • Lab Members
      • Publications
    • Engle Lab
      • Lab Members
    • Fernandez-Godino Lab
      • Lab Members
      • Macular Degeneration
      • Publications
    • Functional Genomics Core (Zebrafish Facility)
      • Lab Members
    • Genetic Counseling Team
      • Team Members
    • Genomics Core Lab
      • Lab Members
    • Liu Lab
      • Lab Members
      • Publications
      • Projects
    • MEEI Bioinformatics Center (MBC)
      • Lab Members
    • Pierce Lab
      • Lab Members
      • Publications
      • Projects
    • Segrè Lab
      • Selected Publications
    • Vandenberghe Lab
      • Lab Members
    • Wiggs Lab
      • Lab Members
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Home
  • Uncategorized
  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting

Featured Posts

  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder

Recent Posts

  • Precision Medicine at Work
  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Ocular Genomics Institute Scientists publish large Gene-Wide Association Study of Glaucoma
  • AAVCOVID Vaccine developed by Luk Vandenberghe to start Clinical trials

Archives

  • June 2021
  • May 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • August 2019
  • May 2019
  • April 2019
  • May 2018
  • April 2018
  • March 2018
  • November 2017
  • September 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017

Categories

  • News
  • Publication
  • Uncategorized

Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
June 3, 2021

  • Caitlin Collin
  • Qin Liu

At the virtual 2021 meeting of the Association for Research in Vision and Ophthalmology (ARVO), Caitlin Collin, PhD, from Mass Eye and Ear (MEE), presented a promising CRISPR/Cas9 gene-editing approach for treating people with autosomal dominant retinitis pigmentosa (adRP) caused by mutations in the gene RP1. The project is funded by the Foundation Fighting Blindness.

Dr. Collin noted that while the development of gene replacement therapies – replacing copies of the mutated gene with normal copies – has strong momentum in clinical trials for retinal diseases, it is better suited for autosomal recessive retinal diseases than those that are autosomal dominant. Different approaches – for example, CRISPR/Cas9 gene-editing – are in most cases better for treating autosomal dominant conditions.

Here is some background on why this is the case. We all have two copies of every gene in every cell in our bodies. Genes express proteins which are essential for our cells’ well-being and function. In recessive disease, both copies of the gene are essentially “dead-in-the-water” and not expressing any protein. By simply replacing these non-functioning genes, we can restore normal protein production.

However, in dominant diseases, things are often more complicated. In many dominant diseases, one gene copy is normal and expresses a normal protein, but the other copy is mutated and expresses a toxic protein that disrupts the function of the normal protein. Therefore to address dominant disease, the mutated gene copy has to be turned off to stop production of the toxic protein.

Dr. Collin and her mentor, Qin Liu, PhD, are developing a CRISPR/Cas9 therapy which works like molecular scissors to snip out strategic locations in the mutated copies of the RP1 gene to turn them off and prevent them from expressing a toxic protein. The normal gene copy is not altered by the therapy. The protein expressed by the normal copies of the RP1 gene is therefore not disrupted and functions normally, thereby halting the disease process. No replacement gene is needed in this case. Furthermore, this approach will work for most people with adRP caused by RP1 mutations, regardless of their mutation.

Dr. Collin’s ARVO presentation highlighted her success with this approach using human retinal cells with RP1 mutations. The MEE team is also evaluating the approach in mice with RP1 mutations. The overall goal is to move the emerging therapy into a clinical trial.

Featured:

Contact Us

243 Charles Street
Boston, MA 02114

Labs

  • Engle Lab
  • Pierce Lab
  • Vandenberghe Lab
  • Wiggs Lab
  • Genomics Core Lab
  • Functional Genomics Core (Zebrafish Facility)
  • MEEI Bioinformatics Center (MBC)

Sitemap

  • Affiliates
  • Careers
  • Meet the Team
  • News & publications
  • Support Our Research
  • Services
  • Privacy
website-boston WebsiteBoston